TVTX missed EPS expectations by 27.29%
Feb 20, 2025, 11:35 PM
-0.94%
What does TVTX do
Travere Therapeutics, based in San Diego, focuses on developing therapies for rare kidney and metabolic diseases, with products like FILSPARI for IgAN and Pegtibatinase for classical homocystinuria. Founded in 2003, the company employs 380 people and also offers Thiola for cystinuria.
Travere Therapeutics (TVTX) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Travere Therapeutics's actual EPS was -$0.73, missing the estimate of -$0.57 per share, resulting in a -27.29% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.